摘要
目的评价门冬胰岛素30联合口服降糖药的3种不同方案用于治疗老年人糖尿病的成本-效果。方法将90例老年糖尿病患者随机分A、B、C3组,每组30例。A组给予门冬胰岛素30(诺和锐30);B组予诺和锐30+二甲双胍(格华止);C组予诺和锐30+阿卡波糖。治疗后比较分析3组的疗效、不良反应及成本-效果。结果 3组临床疗效及低血糖发生率比较差异均无统计学意义(P>0.05);A、B、C3组药物总成本分别为1517.0元、2010.0元和2271.4元。成本-效果比分别为28.5、30.1和32.4;B、C组对于A组对降血糖的增量成本比为36.8元、45.2元。结论 3种治疗疗效均较好,从成本-效果比分析A组更符合药物经济学原则。
Objective To assess the cost-effectiveness of insulin aspart 30 combined with oral hypoglycemic drugs in elderly diabetes patient. Methods 90 elderly diabetes patients were divided into group A, group B and group C, each of 30 ca- ses. Group A was given with insulin aspart 30 ;Group B was given with insulin aspart 30 and mefformin（glucophage） ;Group C was given with insulin aspart 30 and acarbose. After treatment, compared the treatment efficacy, adverse reactions and cost-ef- fectiveness. Results No significant difference was found in clinical effects among the 3 groups （P 〉 O. 05 ）. The total costs for group A,B and group C were 1517.0yuan,2010.0yuan and 2271.4yuan. The cost-effectiveness ratios were 28.5,30. 1 and 32. 4. The hypoglycemic incremental cost of group B and C when compared to group A were 36.8 yuan and 45.2 yuan. Conclu- sion Three kinds of treatment efficacy are all ~ood. Group A accords with the pharmacoeconomics best.
出处
《临床合理用药杂志》
2012年第10期9-10,共2页
Chinese Journal of Clinical Rational Drug Use
